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Abstract
Maintenance of physiologic phosphate balance is of crucial biological importance, as it is fundamental to cellular function,
energy metabolism, and skeletal mineralization. Fibroblast growth factor-23 (FGF-23) is a master regulator of phosphate
homeostasis, but the molecular mechanism of such regulation is not yet completely understood. Targeted disruption of the
Fgf-23 gene in mice (Fgf-23
2/2) elicits hyperphosphatemia, and an increase in renal sodium/phosphate co-transporter 2a
(NaPi2a) protein abundance. To elucidate the pathophysiological role of augmented renal proximal tubular expression of
NaPi2a in Fgf-23
2/2 mice and to examine serum phosphate–independent functions of Fgf23 in bone, we generated a new
mouse line deficient in both Fgf-23 and NaPi2a genes, and determined the effect of genomic ablation of NaPi2a from Fgf-
23
2/2 mice on phosphate homeostasis and skeletal mineralization. Fgf-23
2/2/NaPi2a
2/2 double mutant mice are viable and
exhibit normal physical activities when compared to Fgf-23
2/2 animals. Biochemical analyses show that ablation of NaPi2a
from Fgf-23
2/2 mice reversed hyperphosphatemia to hypophosphatemia by 6 weeks of age. Surprisingly, despite the
complete reversal of serum phosphate levels in Fgf-23
2/2/NaPi2a
2/2, their skeletal phenotype still resembles the one of
Fgf23
2/2 animals. The results of this study provide the first genetic evidence of an in vivo pathologic role of NaPi2a in
regulating abnormal phosphate homeostasis in Fgf-23
2/2 mice by deletion of both NaPi2a and Fgf-23 genes in the same
animal. The persistence of the skeletal anomalies in double mutants suggests that Fgf-23 affects bone mineralization
independently of systemic phosphate homeostasis. Finally, our data support (1) that regulation of phosphate homeostasis is
a systemic effect of Fgf-23, while (2) skeletal mineralization and chondrocyte differentiation appear to be effects of Fgf-23
that are independent of phosphate homeostasis.
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Introduction
Maintaining physiological phosphate balance is essential, not
only for skeletal mineralization but also for various important
biological activities that include cellular signaling, and biochemical
reactions [1]. Acute hypophosphatemia can cause myopathy,
cardiac dysfunction, and hematological abnormalities, whereas
chronic hypophosphatemia impairs bone mineralization, resulting
in rickets and osteomalacia [2]. On the contrary, hyperphospha-
temia is associated with vascular and soft tissue calcifications [3].
Understanding the molecular regulation of phosphate homeostasis
has, therefore, enormous clinical and biological significance.
The kidney is the major site of hormonal-dependent regulation
of phosphate homeostasis, controlling urinary phosphate excretion
according to the needs of the body [1]. Phosphate transport across
the renal proximal tubular epithelial cells is a sodium-dependent
process, driven by the gradient between extracellular and
intracellular sodium concentrations, and such gradient is known
to be maintained by the basolateral membrane–associated Na
+/
K
+-ATPase [4].
The identification of distinct phosphate (Pi) transporters has
increased our understanding of the mechanisms and regulation of
renal and intestinal phosphate handling. The type II family of Na/
Pi co-transporters consists of three highly homologous isoforms:
type IIa (NaPi2a) and type IIc (NaPi2c) are almost exclusively
expressed in the brush-border membrane of the renal proximal
tubules [5–7], whereas type IIb (NaPi2b) is expressed in the
epithelial cells of the small intestine, and is thought to be involved
in intestinal phosphate absorption. The NaPi2b co-transporter is
not expressed in the kidney [8]. Since renal phosphate transport
through NaPi2a is an important mechanism of maintaining
phosphate balance, the molecules that directly or indirectly affect
NaPi2a can influence phosphate homeostasis.
The critical role of NaPi2a co-transporters in the maintenance
of Pi homeostasis was demonstrated by genetic ablation of the
murine NaPi2a gene by homologous recombination. Mice ablated
for the NaPi2a gene (NaPi2a
2/2) exhibit increased urinary
phosphate excretion, resulting in hypophosphatemia [9]. Despite
comparable serum levels of calcium, phosphate, PTH, and
1,25(OH)2D3 NaPi2a
2/2 mice exhibit a ricketic bone phenotype
PLoS Genetics | www.plosgenetics.org 1 August 2008 | Volume 4 | Issue 8 | e1000154at 3 weeks of age; these mutant mice show a normal skeletal
phenotype comparable to wild-type animals at 6 weeks, and have
increased trabecular bone volume at 12 weeks of age [9].
FGF-23 has been shown to be an important regulator of renal Pi
handling. FGF-23 inhibits renal phosphate reabsorption by
suppressing the expression of NaPi2a and NaPi2c co-transporters
[10]. We have recently generated fibroblast growth factor-23 null (Fgf-
23
2/2) mice which are characterized by severe hyperphosphate-
mia, and increased renal expression of NaPi2a [11,12]. In view of
the fact that FGF-23 is a major regulator of phosphate homeostasis
[13–16], this study was designed to assess the pathophysiological
significance of increased renal expression of NaPi2a in Fgf-23
2/2
mice. To test such significance, we have established a new mouse
model by genetically ablating both Fgf-23 and NaPi2a genes in the
same animal, in order to determine whether altered phosphate
homeostasis in Fgf-23
2/2 mice is a NaPi2a-mediated process. In
addition, using this model, we sought to examine phosphate-
independent effects of Fgf-23 on skeletogenesis.
Materials and Methods
Animals
Heterozygous- Fgf-23 and NaPi2a mice were interbred to attain
wild-type, Fgf-23
2/2, NaPi2a
2/2, and Fgf-23
2/2/NaPi2a
2/2
animals at 3 and 6 weeks. Routine PCR was used to identify the
genotypes of various mice as described previously [9,11]. All
studies performed were approved by the institutional animal care
and use committee at the Harvard Medical School.
Bone Densitometry
Bone mineral density (BMD) and bone mineral content (BMC),
were determined on 3- and 6-week-old wild-type, Fgf-23
2/2,
NaPi2a
2/2 and Fgf-23
2/2/NaPi2a
2/2 mice using the PIXImus
small animal dual-energy X-ray absorptiometry (DEXA) system
(Lunar), as described earlier [11]; BMD of the above genotypes
was also measured by peripheral quantitative computerized
tomography (pQCT), as described previously [11,17].
Skeletal Mineralization
The mineralization pattern of the skeleton was analyzed by
Alizarin Red S staining in 6- week-old mice, as described by
McLeod [18].
Histology and Tissue Preparation
All tissues were fixed in 10% buffered formalin. Soft tissues were
routinely processed and embedded in paraffin, cut into 4 mm-thick
sections and stained with hematoxylin and eosin, and von Kossa.
Bone Histology and Histomorphometry
Processing of bone specimens and cancellous bone histomor-
phometry in the distal femoral metaphysis were performed as
described [17,19]. The area within 0.25 mm from the growth
plate was excluded from the measurements.
Biochemical Analyses
Blood was obtained by cheek-pouch bleeding of 3- and 6-week-
old animals. Total serum calcium, serum and urinary phosphorus,
and serum and urinary creatinine levels were determined using
Stanbio LiquiColor (Arsenazo III), Stanbio LiquiUV, and Stanbio
Creatinine kits (Stanbio Laboratory, Boerne, TX), respectively.
Serum PTH levels were measured using a two-sided enzyme-
linked immunosorbent assay (ELISA) specific for intact mouse
PTH (Immunotopics, San Clemente, CA, USA). Serum concen-
trations of 1,25(OH)2D3 were measured using a radioreceptor
assay (Immundiagnostik, Bensheim, Germany). Renal tubular
reabsorption of phosphorus (TRP) was calculated according to the
formula: %TRP=[12(UrP6SeCrea)/(SeP6UrCrea)]6100 (Ur,
urinary; Se, serum; P, phosphorus; Crea, creatinine).
Parathyroid Hormone (PTH) Injections
Wild-type, Fgf-23
2/2, and NaPi2a
2/2 mice at 4-weeks of age,
were injected subcutaneously with vehicle (saline), PTH peptide
(1–34), or PTH peptide (3–34) (50 nmol of peptide per Kg of body
weight). Blood was collected by cheek-pouch bleeding prior to
injections, as well as 2 hours post-injections, and serum phosphate
levels were measured using Stanbio LiquiUV kit (Stanbio
Laboratory, Boerne, TX).
In Situ Hybridization
Complementary
35S-UTP-labeled riboprobes (complementary
RNAs for collagen type X (Col X), dentin matrix protein-1 (DMP-
1), and osteopontin (OPN)) were used for performing in situ
hybridization on paraffin sections, as described previously [20].
Western Blotting
Fresh kidney cortex was isolated from 3 week old mice, and
homogenized in HbA buffer (pH 7.4) containing 20 mM Tris
base, 5 mM MgCl2, 5 mM Na2HPO4, 1 mM EDTA and 80 mM
sucrose and protease inhibitor cocktail tablets (Complete Mini,
EDTA-free; Roche). Protein concentration was determined by
performing BCA protein assay (Pierce), using BSA as a standard.
Protein samples were heated at 95uC for 5 min in sample buffer
containing 2% SDS and 1% 2-mercaptoethanol, and were
subjected to 10% SDS-polyacrylamide gel electrophoresis. The
separated proteins in the gel were transferred electrophoretically to
Hybond-P polyvinylidenedifluoride transfer membranes. After
incubation in blocking solution, the membranes were further
treated with diluted rabbit affinity-purified anti-type 2c NaPi co-
transporter antibody (1:500), a generous gift of Dr Ken-ichi
Miyamoto, Japan. Mouse anti-actin monoclonal antibody (SIG-
MA) was used as an internal control. Horseradish peroxidase-
Author Summary
Regulation of phosphate homeostasis is a tightly con-
trolled hormonal process involving the intestine, kidneys,
and bone, and imbalance of this homeostasis may
influence overall mineralization. Fibroblast growth factor-
23 (FGF-23) is a circulating hormone produced in the bone
that mainly targets the kidneys to control the activity of
the sodium/phosphate co-transporters NaPi2a and NaPi2c.
These transporters are responsible for actively reabsorbing
phosphate ions into the body to maintain physiological
serum phosphate levels. Changes in FGF-23 activity lead to
human disorders associated with either phosphate wast-
ing or retention. Genetically altered mice in which Fgf-23
activity is lost exhibit severe hyperphosphatemia accom-
panied by increased NaPi2a activity, and they develop
abnormal bone mineralization. Here we describe a new
mouse model in which we eliminated NaPi2a from Fgf-23
null mice and show reversal of hyperphosphatemia to
hypophosphatemia, suggesting that NaPi2a is the major
regulator of phosphate homeostasis. However, the skeletal
mineralization defect observed in mice lacking Fgf-23
function remained unchanged in the absence of NaPi2a in
these mice. Thus our data indicate that Fgf-23 has a role in
controlling bone mineralization independent of systemic
phosphate levels.
Role of NaPi2a in the Phenotype of Fgf-23
2/2 Mice
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secondary antibody (Jackson ImmunoResearch Laboratories), and
signals were detected by the SuperSignal West Pico Chemilumi-
nescent Substrate system (Pierce).
Mouse Calvarial Cell Culture
Mouse calvarial cell culture was carried out as previously
described [21] with modifications. Briefly, mouse calvarial cells
were isolated from 3–5 day old C57BL/6J wild-type mice.
Calvariae (parietal bones) were removed aseptically, and they
were sequentially digested with 2 mg/ml collagenase solution
containing collagenase type I and type II in 1:3 ratio. (collagenase
type I and type II; Worthington, Newark, NJ). Osteoblast enriched
fractions (the last four of six fractions) were cultured for five to
seven days until confluence in a-MEM supplemented with 10%
FBS and 1% Penicillin-Streptomycin (Invitrogen Life Technolo-
gies, Baltimore, MD). Adherent cells were trypsinized and re-
plated at a density of 2.5610
4/cm
2 in the same medium
supplemented additionally with 50 mg/ml ascorbic acid and
10 mM b-glycerophosphate (bGP) to induce matrix mineralization
with or without treatment with 10 ng/ml of human FGF-23
(hFGF-23). Alizarin Red S staining was performed 21 days after
subculture in mineralization medium with or without FGF-23
treatment.
Statistics
Statistically significant differences between groups were evalu-
ated by Student’s t-test for comparison between two groups or by
one-way analysis of variance (ANOVA) followed by Tukey’s test
for multiple comparisons. All values were expressed as mean 6SE.
A p value of ,0.05 was considered to be statistically significant. All
analyses were performed using Microsoft Excel and GraphPad
Prism 4.0.
Results
Generation of Fgf-23
2/2/NaPi2a
2/2 Compound Mutants
In vivo ablation of Fgf-23 results in significantly elevated serum
phosphate levels accompanied by enhanced renal phosphate
reabsorption and a significant increase in expression and activity
of NaPi2a [11,22,23]. To test the hypothesis that increased NaPi2a
activity is responsible for the severe hyperphosphatemia in
Fgf-23
2/2 animals, we generated a new mouse model deficient in
both the Fgf-23 and the NaPi2a genes (Fgf-23
2/2/NaPi2a
2/2
compound mutants) by interbreeding heterozygous- Fgf-23 and
NaPi2a mice. The mice studied were of C57BL/6J genetic
background and animals examined were littermates. Compound
mutants were viable and were born at the expected Mendelian
frequency. In the current study, we compared and analyzed gross
phenotypes, and obtained morphological and biochemical data
from wild-type, Fgf-23
2/2, Fgf-23
2/2/NaPi2a
2/2, and NaPi2a
2/2
animals.
Macroscopic Phenotype of Fgf-23
2/2/NaPi2a
2/2
Compound Mutants
At birth, Fgf-23
2/2/NaPi2a
2/2 mice appear indistinguishable
from their normal littermates. At 3 weeks Fgf-23
2/2/NaPi2a
2/2
compound mutants are larger in size than Fgf-23
2/2 mice
(8.661.7 g vs 6.860.38 g), but are slightly smaller than wild-type
(10.960.2 g), and similar to NaPi2a
2/2 single knock-out animals
(7.961.1 g). At 6 and 12 weeks of age, compound mutants are still
smaller than wild-type littermates (12.260.7 g vs 20.760.2 g at 6
weeks), but their body weight is significantly higher than that of
Fgf-23
2/2 mice (6.560.2 g) (Figure 1A and B). Apart from the
slightly reduced body size, double mutants do not show any
obvious gross abnormalities with regard to movement and physical
activities, whereas Fgf-23
2/2 littermates have severely weakened
Figure 1. Macroscopic phenotype of Fgf-23
2/2/NaPi2a
2/2 double mutants. (A) Gross phenotype of control, Fgf-23
2/2, Fgf-23
2/2/NaPi2a
2/2,
and NaPi2a
2/2 animals at 6 weeks of age. (B) Growth curves and (C) survival ratios for all four genotypes. Data are represented as mean 6SEM
(** p,0.01).
doi:10.1371/journal.pgen.1000154.g001
Role of NaPi2a in the Phenotype of Fgf-23
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addition, Fgf-23
2/2/NaPi2a
2/2 survive longer than Fgf-23
2/2
mice (Figure 1C).
Bone Densitometry
To evaluate the effects of NaPi2a gene ablation on the skeleton of
Fgf-23
2/2 animals, bone densitometric measurements of hind limbs
from 3- and 6-week old control, Fgf-23
2/2, Fgf-23
2/2/NapI2a
2/2,
and NaPi2a
2/2 littermates were carried out using PIXImus and
pQCT (Figure 2). PIXImus analysis showed significantly increased
total body bone mineral content (BMC) in Fgf-23
2/2 mice when
compared to wild-type controls at both ages (0.01660.002 vs.
0.01260.0007 at 3 weeks and 0.04860.006 vs. 0.01660.0003 at 6
weeks) (Figure 2A). In contrast, the BMC of Fgf-23
2/2/NaPi2a
2/2
compound mutants was similar to control littermates at 3 weeks
(0.01260.002) but it was significantly elevated at 6 weeks
(0.022560.001), although it was significantly lower when compared
to Fgf-23
2/2 mice (Figure 2A). In accordance with previous reports
[9], the total body BMC of NaPi2a
2/2 mice at both ages was
comparable to wild-type animals (Figure 2A).
Bone densitometric measurements using PIXImus and pQCT
demonstrated decreased areal and volumetric bone mineral
density (BMD) in the hindlimbs and in the distal femoral
metaphysis of Fgf-23
2/2 mutant mice at both 3 and 6 weeks of
age (Figure 2B and C). The bones of NaPi2a
2/2 single knock-out
mice demonstrated a significantly reduced BMD at 3 weeks, which
was nearly normalized by 6 weeks (Figure 2B and C), in accord
with earlier published observations [9]. Areal and volumetric
BMD of Fgf-23
2/2/NaPi2a
2/2 compound mutants was not
significantly different from that of control littermates at 3 weeks
(Figure 2B and C). However, at 6 weeks, volumetric BMD was
significantly higher in compound mutants compared with Fgf-23
2/
2 mice, but still lower than in wild-type controls (Figure 2C).
Serum and Urine Biochemical Parameters
Phosphate, calcium, 1,25(OH)2D3 and parathyroid hormone
(PTH) levels were measured in 3- and 6-week-old wild-type, Fgf-
23
2/2,Fgf-23
2/2/NaPi2a
2/2,a n dNaPi2a
2/2 animals. Fgf-23
2/2
mice were severely hyperphosphatemic at both 3 and 6 weeks of age
(15.960.8 and 14.160.2 mg/dl, respectively) when compared to
control littermates (9.660.1 and 8.860.4 mg/dl, respectively).
However, Fgf-23
2/2/NaPi2a
2/2 animals were normophosphate-
mic at 3 weeks (8.860.6 mg/dl), and became hypophosphatemic
with significantly lower serum phosphate levels (5.260.6 mg/dl) by
6 weeks, comparable to those found in NaPi2a
2/2 animals of the
same age (5.360.1 mg/dl) (Figure 3A). More importantly,
decreased urinary phosphate excretion (normalized to urinary
creatinine) in Fgf-23
2/2 mice (2.460.1 vs 4.460.2 in control
littermates at 3 weeks and 2.560.3 vs 5.460.7 at 6 weeks) was
reversed in Fgf-23
2/2/NapI2a
2/2 double mutant animals. Com-
pound mutants showed hyperphosphaturia (5.260.1 at 3 weeks and
6.861.6 at 6 weeks), similar to the one found in NaPi2a
2/2 mice
(6.860.3 and 5.360.7 respectively) (Figure 3D). In addition, Fgf-
23
2/2/NaPi2a
2/2 animals had reduced fractional renal tubular
reabsorption of phosphate (TRP) (51.9612.4 and 50.469.6 % at 3
and 6 weeks respectively) when compared to Fgf-23
2/2 mice
(90.563.2 and 80.460.1 %) and wild-type littermates (82.466.8
and 67.9614.3 %) (Figure 3E). Collectively, these results suggest
that increased renal phosphate reabsorption due to increased
NaPi2aactivityisthemajorcauseforabnormalhyperphosphatemia
in Fgf-23
2/2 mice.
Serum calcium levels were found to be higher in all three mutant
mouse lines at 3 weeks of age. At 6 weeks, the calcium levels in
NaPi2a
2/2 (11.160.05 mg/dl) and Fgf-23
2/2/NapI2a
2/2 com-
pound mutants (15.761.3 mg/dl) were significantly higher than in
Fgf-23
2/2 mice (10.160.2 mg/dl) (Figure 3B). The considerable
elevation in serum calcium levels in all mutants is probably due to
excessive vitamin D signaling, as reflected by the significantly
increased serum 1,25(OH)2D3 levels in these mice (Figure 3F).
Probably as a result of high serum 1,25(OH)2D3 and concomitant
hypercalcemia, serum PTH was undetectable in all three mutant
lines (Figure 3G). The calcium-phosphate product was severely
increased in 3- and 6-week-old Fgf-23
2/2 mice relative to wild-type
controls (Figure 3C). Compound mutants showed only a slight
increase in the calcium-phosphate product at 3 weeks, but did not
exhibit any significant difference from wild type animals at 6 weeks
of age, whereas the calcium-phosphate product was significantly
reduced in Napi2a
2/2 mice (Figure 3C).
Figure 2. Bone mineralization analysis. (A) Total bone mineral
content (BMC; each value obtained for BMC was normalized to the body
weight of the corresponding animal). (B) Bone mineral density (BMD) of
hind-limbs by Piximus, and (C) pQCT of control, Fgf-23
2/2, Fgf-23
2/2/
NaPi2a
2/2, and NaPi2a
2/2 animals. (Statistical significance * p,0.05,
** p,0.01,*** p,0.001. Black asterisks represent comparison with
control, red with Fgf-23
2/2, and blue with Fgf-23
2/2/NaPi2a
2/2).
doi:10.1371/journal.pgen.1000154.g002
Role of NaPi2a in the Phenotype of Fgf-23
2/2 Mice
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serum phosphate levels in wild-type and Fgf-23
2/2 treated mice,
but did not reduce the serum phosphate concentration in NaPi
2a
2/2 mice (Figure 3F). Injection of vehicle (saline) or inactive
PTH peptide (3–34) had no effect on serum phosphate levels.
Skeletal Phenotype
To examine the mineralization pattern of the bones, Alizarin
Red S staining was performed on full body skeletons of 6-week-old
Fgf-23
2/2/NaPi2a
2/2 mutants and was compared to wild-type,
Fgf-23
2/2, and NaPi2a
2/2 animals. The skeletal phenotype of Fgf-
23
2/2/NaPi2a
2/2 compound mutants resembled the one seen in
Fgf-23
2/2 animals with typically widened ribs, whereas bones
from NaPi2a
2/2 mutant mice were comparable to wild-type mice
(Figure 4A).
In agreement with the bone densitometric data, histological
analysis of methylmethacrylate sections from femurs showed
almost normal bone architecture in Fgf-23
2/2/NaPi2a
2/2 double
mutants at 3 weeks (Figure 4B). In contrast, the histological bone
phenotype of Fgf-23
2/2/NaPi2a
2/2 double mutants closely
resembled that of Fgf-23
2/2 mice at 6 weeks (Figure 4C). The
bones of 6-week old Fgf-23
2/2 and Fgf-23
2/2/NaPi2a
2/2 mice
exhibited a decreased number of hypertrophic chondrocytes,
hypermineralization adjacent to the growth plate in the primary
spongiosa, and severe osteoidosis in the secondary spongiosa
(Figure 4B). Bones from NaPi2a
2/2 mice at 3 and 6 weeks
appeared normal at the histological level (Figure 4B).
Quantitative histomorphometry (Table 1) revealed a striking
increase in osteoid volume and osteoid thickness in Fgf-23
2/2
mice at 3 and 6 weeks of age. Interestingly, osteoid thickness was
normal in 3-week-old compound mutants and NaPi2a
2/2 animals,
although osteoid volume and surface was increased in NaPi2a
2/2
mice relative to wild-type controls. Similar to the histological
appearance of the bones, histomorphometry confirmed the severe
mineralization defect in Fgf-23
2/2 mice and Fgf-23
2/2/NaPi2a
2/2
compound mutants at 6 weeks of age, as evidenced by similar
Figure 3. Biochemical measurements. (A) serum phosphate, (B) serum calcium, (C) calcium-phosphate product, (D) urinary phosphate, (E)
fractional renal tubular reabsorption of phosphate (TRP), (F) serum 1,25(OH)2D3, and (G) serum PTH levels in control, Fgf-23
2/2, Fgf-23
2/2/NaPi2a
2/2,
and NaPi2a
2/2 animals. (H) serum phosphate levels before and after injections with vehicle, PTH (1–34) or PTH (3–34). (Statistical significance
*p,0.05, **p,0.01, *** p,0.001. Black asterisks represent comparison with control, red with Fgf-23
2/2, and blue with Fgf-23
2/2/NaPi2a
2/2.)
doi:10.1371/journal.pgen.1000154.g003
Role of NaPi2a in the Phenotype of Fgf-23
2/2 Mice
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Six-week-old NaPi2a
2/2 mice had normal osteoid thickness and
osteoid volume.
Collectively these data demonstrate that the defect in bone
mineralization seen in hyperphosphatemic Fgf-23 mutants is also
present in 6-week-old hypophosphatemic Fgf-23
2/2/NaPi2a
2/2
mice despite the opposite serum phosphate levels. Thus, the
mineralization defect in Fgf-23
2/2 mutants and Fgf-23
2/2/
NaPi2a
2/2 compound mutants appears to be due to lack of Fgf-
23 gene expression rather than systemic phosphate homeostasis.
Moreover, NaPi2a
2/2 littermates which completely resemble the
serum biochemistry of Fgf-23
2/2/NaPi2a
2/2 animals, did not
exhibit any defects in bone mineralization at 6 weeks of age.
Gene Expression
To analyze the gene expression pattern of bone cells and to
examine the effect of Fgf-23 and NaPi2a gene deletion on
skeletogenesis, we performed in situ hybridization on paraffin
sections prepared from tibias of wild-type, Fgf-23
2/2, Fgf-23
2/2/
NaPi2a
2/2, and NaPi2a
2/2 animals at 3 and 6 weeks of age
(Figure 5). Similar to our previous findings [11,23], the number of
hypertrophic chondrocytes was reduced in Fgf-23
2/2 animals at
both ages, relative to control mice, as demonstrated by the marked
decrease in collagen type X expression (Figure 5A). Similarly, Fgf-
23
2/2/NaPi2a
2/2 compound mutants also showed a significant
reduction in the number of hypertrophic chondrocytes at 6 weeks,
comparable to Fgf-23
2/2 animals, although collagen type X
Figure 4. Histological analysis of bones by von Kossa and Alizarin Red S staining. (A) Alizarin Red S stained ribs from all genotypes at 6
weeks of age. (B) Three-mm-thick undecalcified sections from 3- and (C) 6 week-old control, Fgf-23
2/2, Fgf-23
2/2/NaPi2a
2/2, and NaPi2a
2/2 bones
were stained with von Kossa/McNeal. Top panels: tibial growth plate and trabecular bone (magnification x100); lower panels: tibial secondary
spongiosa (magnification x400). Black staining represents mineralization. At 6 weeks, more mineral deposition is found in the area below the growth
plate (methaphysis) in Fgf-23
2/2 mice and Fgf-23
2/2/NaPi2a
2/2 double mutants. In addition, areas of unmineralized osteoid (light blue) are found
similarly in the secondary spongiosa of Fgf-23
2/2 and Fgf-23
2/2/NaPi2a
2/2 mice.
doi:10.1371/journal.pgen.1000154.g004
Role of NaPi2a in the Phenotype of Fgf-23
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contrast, we noted a marked increase of collagen type X-positive
cells in NaPi2a
2/2 mice, especially at 3 weeks of age (Figure 5A).
Furthermore, we examined expression of osteopontin (OPN) and
dentin matrix protein (DMP-1), two members of the SIBLING
protein family that exert key biological effects in skeletal
mineralization. An association between FGF23 and DMP-1 has
been suggested in earlier studies [24]. For instance, increased
serum FGF-23 levels were found in patients with autosomal
recessive hypophosphatemic rickets (ARHR), a disease caused by
mutation in DMP-1 gene [24]. Similarly, in Dmp-1 null mice Fgf-
23 levels were high [25]. In our study, lack of Fgf-23 resulted in
increased expression of DMP-1 and OPN in Fgf-23
2/2 and Fgf-
23
2/2/NaPi2a
2/2 compound mutants at both 3 and 6 weeks. In
contrast, NaPi2a
2/2 animals exhibited normal DMP-1 and OPN
at 3 weeks, however, the expression of both of these genes
appeared to be decreased in NaPi2a
2/2 animals at 6 weeks,
compared to wild-type controls (Figure 5B).
Morphology of Soft Tissue Anomalies in Fgf-23
2/2/
NaPi2a
2/2 Mice
Histological examination of various soft tissues from Fgf-23
2/2/
NaPi2a
2/2 double mutants showed that abnormalities such as
intestinal atrophy and lung emphysema that are consistently
observed in single Fgf-23
2/2 animals, were ameliorated, but not
completely abolished in Fgf-23
2/2/NaPi2a
2/2 double mutants,
suggesting that these soft tissue pathological changes are partially
caused by the severely increased serum phosphate levels in Fgf-
23
2/2 mice (Figure 6).
Effect of FGF-23 on the Mineralization of Mouse Calvarial
Osteoblasts
To evaluate the effect of FGF-23 on mineralization we cultured
osteoblastic cells isolated from C57BL/6J wild-type calvariae in
mineralization medium alone (vehicle) or mineralization medium
containing hFGF-23 protein. Alizarin Red S staining was carried
out after 21 days. A marked decrease in mineralized bone nodule
formation was evident in cells treated with hFGF-23 when
compared to vehicle treated cells (Figure 7). These data suggest
that excess of FGF-23 in osteoblast cultures leads to an impairment
of mineralization in vitro.
Discussion
This is the first study using a genetic mouse model with dual
ablation of the NaPi2a and Fgf-23 genes. Fgf-23
2/2 mice develop
severe hypercalcemia, hyperphosphatemia, hypervitaminosis D,
and osteomalacia starting in early life [11,22]. The hyperphos-
phatemia in Fgf-23
2/2 mice is associated with increased renal
phosphate uptake, and increased expression of the renal Na/Pi2a
co-transporter in the proximal tubular epithelial cells [26]. In our
study, ablation of both NaPi2a co-transporter and Fgf-23 in the
same animal resulted in reduced serum phosphate levels which
were accompanied by increased urinary phosphate excretion in
Fgf-23
2/2/NaPi2a
2/2 mice, reemphasizing the fact that increased
NaPi2a activity in the renal proximal tubular epithelial cells is
responsible for the severe hyperphosphatemia in Fgf-23
2/2 mice.
These results provide compelling genetic evidence of the
importance of NaPi2a in regulating renal phosphate homeostasis
in Fgf-23
2/2 mice. Deletion of NaPi2a from these animals and
accompanied changes in serum phosphate levels significantly
improved the abnormal phenotype associated with lack of Fgf-23
activities, indicating that the high phosphate microenvironment
contributes to the development of widespread soft tissue atrophy
and calcifications in Fgf-23
2/2 mice. Similar observations were
made in recent studies in which the increased vitamin D signaling
in Fgf-23
2/2 mice was blocked by additionally ablating the renal
1a-hydroxylase or the vitamin D receptor [23,27], or in which Fgf-
23
2/2 mice were fed a low phosphate diet [3]. In addition, our
study suggests that hypervitaminosis D is toxic when associated
with an increased calcium-phosphate product.
The mechanisms behind the upregulation of NaPi2a expression
and activity in Fgf-23
2/2 mice are still poorly understood. The
retrieval and recruitment of NaPi2a proteins is a complex multi-
factorial process, and the in vivo interactions between FGF-23,
vitamin D, PTH, and NaPi2a transporters need additional studies
for comprehensive understanding. Earlier studies have shown that
administration of FGF-23 increases urinary phosphate excretion
by suppressing renal expression of sodium-phosphate co-trans-
porters [28]. Therefore, the upregulation in NaPi2a protein in Fgf-
23
2/2 mice may be a direct effect of Fgf-23 ablation. On the other
hand, high 1,25(OH)2D3 and suppressed PTH in Fgf-23
2/2 mice
could also be involved. PTH is a powerful inhibitor of renal
phosphate reabsorption by facilitating endocytosis of the NaPi2a
transporters from the brush-border membrane of proximal tubular
epithelial cells for eventual lysosomal degradation [29,30]. To test
the hypothesis that suppressed serum PTH in Fgf-23
2/2 mice
could diminish or delay the endocytosis of the NaPi2a transporters
from the proximal tubular epithelial cells, we injected vehicle
(saline), PTH (1–34) and PTH (3–34) into Fgf-23
2/2 and
NaPi2a
2/2 mice. We found that a single injection of bioactive
PTH (1–34) can significantly reduce serum phosphate levels in
wild-type and Fgf-23
2/2 mice (Figure 3H). In contrast, no effect of
PTH (1–34) injection on serum phosphate levels was noted in
Table 1. Bone histomorphometry data.
Variable Control Fgf-23
2/2
Fgf-23
2/2/
NaPi2a
2/2 NaPi2a
2/2
3 weeks
BV/TV (%) 13.7466.39 13.7568.95 8.9864.62 10.4464.36
OV/BV (%) 7.3662.31 32.09617.42
a* 12.1667.03
a{ 19.2468.19
a*
OS/BS (%) 25.6664.32 52.4866.66
b* 38.4867.34 42.8067.49
a*
ObS/BS (%) 12.6166.98 7.4865.25 12.7067.83 20.39610.95
OTh (mm) 2.8360.58 6.9261.79
b* 3.1160.73
b{ 3.4860.74
b{
TbTh (mm) 16.0562.45 17.5561.61 16.2963.01 16.0064.79
TbSp (mm) 116.94648.97 159.56115.78 226.326151.89 169.356120.82
TbN (1/mm) 8.5663.56 7.6064.30 5.5463.11 7.6164.95
6 weeks
BV/TV (%) 9.8863.70 10.5663.02 26.2968.43 14.63611.92
OV/BV (%) 3.0462.18 47.44611.67
d* 27.4468.34
d* 5.7862.67
a{,b {
OS/BS (%) 14.2864.28 42.3063.40
b* 42.8967.99
b* 30.7968.86
ObS/BS (%) 16.7566.76 5.2665.04 4.1960.60 19.5164.56
OTh (mm) 2.3960.95 10.1163.84
c* 11.1662.85
d* 2.9860.94
a{,b {
TbTh (mm) 24.8164.49 25.2061.16 37.0669.94 28.7669.36
TbSp (mm) 242.83657.39 230.04687.74 111.94654.84 218.986104.24
TbN (1/mm) 3.8960.91 4.2061.22 7.3662.50 4.6162.24
BV/TV, bone volume; OV/BV, osteoid volume; OS/BS, osteoid surface; ObS/BS,
osteoblast surface; OTh osteoid thickness; TbTh, trabecular thickness; TbSp,
trabecular separation; TbN, trabecular number.
a p,0.05,
b p,0.01,
c p,0.001.
* represents comparison with control, { with Fgf-23
2/2, and { with Fgf-23
2/2/
NaPi2a
2/2.
doi:10.1371/journal.pgen.1000154.t001
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2/2 mice emphasizing that Napi2a is the dominant sodium
phosphate co-transporter in the renal proximal tubule cells and
responsible for the severe hyperphosphatemia in Fgf-23
2/2 mice.
As expected, injections of vehicle or inactive PTH (3–34) did not
have any effect on serum phosphate levels in all mice examined.
NaPi2c, another sodium phosphate co-transporter in the renal
proximal tubule cells was upregulated in Fgf-23
2/2, Fgf-23
2/2/
NaPi2a
2/2, and NaPi2a
2/2 mice when compared to wild type
littermates (Figure S1). From these results we conclude that 1)
reduced level of PTH in Fgf-23
2/2 mice could contribute to the
upregulation of NaPi2a expression in these mice and thereby to
the development of hyperphosphatemia, and 2) compensatory
increased expression of NaPi2c cannot efficiently restore the effects
of NaPi2a loss.
The main source of Fgf-23 production has been shown to be the
osteocyte[23,31].We,therefore,analyzed the skeletonofFgf-23
2/2
/NaPi2a
2/2 compound mutants, in which serum phosphate levels
were reversed to hypophosphatemia. Surprisingly, skeletal abnor-
malities observed in Fgf-23
2/2 mice including the decrease in
hypertrophic chondrocytes in the growth plate, the increased
mineral deposition adjacent to the growth plate, and the
osteomalacic phenotype were found to be similar in 6-week-old
Fgf-23
2/2/NaPi2a
2/2 compound mutants, despite their signifi-
cantly reduced serum phosphate levels. Furthermore, our data
conclusively show that the osteomalacic phenotype in Fgf-23
2/2
and Fgf-23
2/2/NaPi2a
2/2 compound mutants at 6 weeks of age is
not caused by changes in serum phosphate levels. Rather, our
findings suggest that the increased 1,25(OH)2D3 serum levels,
Figure 5. In situ hybridization. Riboprobes for (A) collagen type X (Col X), (B) dentin matrix protein-1 (DMP-1), and osteopontin (OPN) on sections
from tibia of control, Fgf-23
2/2, Fgf-23
2/2/NaPi2a
2/2, and NaPi2a
2/2at 3 and 6 weeks.
doi:10.1371/journal.pgen.1000154.g005
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levels, cause osteomalacia in Fgf-23
2/2 mice. In line with this
notion, studies have convincingly demonstrated that rats treated
with high doses of 1,25(OH)2D3 have impaired bone mineralization
[32,33].
A recent study has demonstrated that NaPi2a is expressed in
mouse MC3T3-E1 and rat UMR-106 osteoblast-like cells and its
expression is regulated by phosphate [34], supporting a role of
NaPi2a in mediating phosphate transport in osteoblasts. Therefore
ablation of NaPi2a could affect bone mineralization. However,
although both NaPi2a
2/2 and Fgf-23
2/2/NaPi2a
2/2 compound
mutants lack NaPi2a and have similar biochemical parameters,
they exhibit a different skeletal phenotype. One obvious difference
between these two mouse models however is the lack of Fgf-23
expression, suggesting that Fgf-23 has a significant role in bone
mineralization. This hypothesis is strengthened by in vitro studies
by Wang et al in which they show that adenoviral overexpression of
FGF-23 in rat calvarial cells inhibits bone mineralization
independent of systemic effects on phosphate homeostasis [35].
In addition, we have pursued ex vivo-in vitro studies by isolating and
culturing mouse calvarial osteoblasts from wild-type mice and
exposing them to FGF-23 treatment. Our data demonstrate that
FGF-23 treatment of primary calvarial osteoblasts from wild-type
mice leads to an inhibition of mineralization as shown by the
decrease in Alizarin staining (Figure 7). Moreover, we could
confirm the previously published data which show a reduction in
mineralization using osteoblasts isolated from Hyp mice, which
produce high levels of Fgf-23, again emphasizing that FGF-23 is a
potent inhibitor of mineralization [36,37 and data not shown].
Taken together, these results suggest that excess of FGF-23 can
negatively regulate bone mineralization. However, the mechanism
responsible for the effect of FGF-23 on bone mineralization, as
well as the role of Klotho, if any, in the Fgf-23-specific signaling in
osteoblasts in vivo remain to be determined.
The expression pattern of the two sibling proteins, OPN and
DMP-1 in bones of wild type, Fgf-23
2/2 and Fgf-23
2/2/NaPi2a
2/
2 and NaPi2a
2/2 at 3 and 6 weeks of age demonstrated phosphate
independent effect of Fgf-23 on bone. Previous in vitro studies using
wild-type murine cementoblasts, have shown phosphate-depen-
dent regulation of DMP-1 and OPN [38]. Interestingly, however,
we have found that expression of DMP-1 and OPN in bones from
Fgf-23
2/2 and Fgf-23
2/2/NaPi2a
2/2 compound mutants is
significantly upregulated at 3 and 6 weeks of age. Thus, in the
absence of Fgf-23 activity, increased expression of DMP-1 and
OPN appears to be independent of circulating phosphate levels
and might, therefore, be partly mediated through direct effects of
Fgf-23 on these SIBLING genes, but such a hypothesis needs to be
further investigated.
In summary, the phenotype of Fgf-23
2/2/NaPi2a
2/2 compound
mutants demonstrates that 1) increased NaPi2a activity is the main
cause for the severe hyperphosphatemia observed in Fgf-23
2/2
mice, 2) that the mineralization defect and the growth plate changes
in Fgf-23
2/2 and Fgf-23
2/2/NaPi2a
2/2 compound mutants at 6
weeks of age are partly due to lack of Fgf-23 function rather than
systemic phosphate homeostasis, and 3) that the altered expression
of the sibling proteins OPN and DMP1 in bone is independent of
serum phosphate levels in mice ablated for Fgf-23. Genetic ablation
of NaPi2a from Fgf-23
2/2 mice reversed the hyperphosphatemia to
hypophosphatemia, and partially improved the soft tissue calcifica-
tionsandatrophy.AnalysisofthebonesfromFgf-23
2/2/NaPi2a
2/2
compound mutants revealed that the osteomalacic bone phenotype
inmicelacking Fgf-23isnotalwaysassociated with serum phosphate
levels. Further analyses are needed to determine the detailed
molecular interactions of Fgf-23 with genes responsible for skeletal
mineralization.
Figure 6. Histologicalanalysisofsofttissues. Hematoxylin and Eosin-stained sections of intestines and lungs from 6 week-old control, Fgf-23
2/2,
Fgf-23
2/2/NaPi2a
2/2, and NaPi2a
2/2. Intestinal sections from Fgf-23
2/2 mice reveal reduced height of intestinal villi and atrophy of intestinal
mucosa. In addition, Fgf-23
2/2 mice exhibit lung emphysema. These features are significantly improved in Fgf-23
2/2/NaPi2a
2/2 mice (magnification
62.5).
doi:10.1371/journal.pgen.1000154.g006
Figure 7. Alizarin Red S staining of wild-type calvarial
osteoblasts treated with either mineralization medium alone
or with medium containing hFGF23 protein for 21 days. Top
panels show vehicle treated wild-type cells (n=15) and bottom panels
show wild-type cells treated with hFGF-23 (n=15).
doi:10.1371/journal.pgen.1000154.g007
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Figure S1 Expression of NaPi2c in renal cortex by Western
Blotting. Actin was used as internal control.
Found at: doi:10.1371/journal.pgen.1000154.s001 (1.77 MB TIF)
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